Netherlands-based VectorY Therapeutics BV has raised €74.5 million to support development of new products for neurodegenerative diseases using a vector technology that enables the production of therapeutic antibodies in vivo. The financing includes new investors Angelini Ventures, Invest-NL of the Netherlands and the European Investment Bank. A group of returning investors including Forbion and Eli Lilly & Co also participated.
A spin-out from the University of Oxford, UK, has raised £67 million from a Series A financing to advance clinical development of a new monoclonal antibody for treating essential thrombocythaemia (ET), a rare blood cancer. Alethio Therapeutics Ltd is building a portfolio of medicines to treat myeloproliferative neoplasms of which ET is one.
Germany-based Boehringer Ingelheim GmbH has broadened a two-year oncology agreement with Sino Biopharmaceutical Ltd of Hong Kong, enabling the two parties to explore treatments based on antibody-drug conjugates (ADCs) and T cell engagers. The companies launched their first collaboration in 2024 when BI agreed to supply Sino, now known as the SBP Group, with a small group of experimental drugs for further development.
Research Strategy
RNA-based therapeutics, both present and future
By Jon Moore
Neuroscience
The promise of precision medicine
By Michelle Lax
Commentary
How multi-omics supports drug development
By Edita Karosiene
Regulation and Policy
New FDA guidance for psychedelic drugs
By Peter Charlish
Stock Market Performance
Q3 valuations shaped by AI, dealmaking
By Sean Morgan-Jones
RNA-based therapeutics, both present and future
(443.22 KB)
